Hikma Pharmaceuticals is a multinational pharmaceutical company founded in Amman, Jordan, in 1978. Headquartered in London, the company develops, manufactures and markets a broad range of branded and non-branded generic medicines, as well as speciality injectable products. Over four decades, Hikma has grown from a regional pharmaceutical supplier to a global healthcare provider, maintaining a focus on quality manufacturing and regulatory compliance.
The company operates across three core business segments: branded generics, speciality injectables and non-branded generics. Its branded generics portfolio offers treatments in therapeutic areas such as cardiovascular, gastroenterology and pain management, primarily targeting emerging markets in the Middle East and North Africa. The speciality injectables segment includes oncology, anaesthesia and critical-care products, while the non-branded generics arm supplies a broad range of oral and injectable medicines to established markets in Europe and North America.
Hikma maintains a network of manufacturing facilities and R&D centres in Jordan, Portugal, the United Kingdom, Italy and the United States, enabling the company to serve customers in more than 50 countries. With an experienced executive leadership team and a board chaired by representatives of its founding Darwazah family, Hikma continues to pursue growth through strategic partnerships, targeted acquisitions and ongoing investment in product development and regulatory affairs.
AI Generated. May Contain Errors.
Free HKMPY Stock Alerts